ClinicalTrials.gg
RecruitingNCT07711288Updated Nov 12, 2026

A Two-part Study of Lembas Edge Evaluating Tolerability and Postprandial Glycemic Control

An interventional study of Low dose alpha-galactosidase-derived peptide and Medium dose alpha-galactosidase-derived peptide in Postprandial Glycemic Control and Prediabetic Overweight and Obese Adults, sponsored by Lembas. Recruiting at 1 site in Canada. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Lembas · Not applicable, Interventional, and Treatment

Updated Nov 12, 2026Now RecruitingSite recruiting status changed+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
35
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 189 studies in Overweight with a site in Canada — 45 open to participants now, 68 under way, 33 of them phase 3. Overweight · Canada.

Planned enrollment
129th of 160
35 · median 119
Started
2026
with 37 others
No phase
79 of 189
14 open now
Primary completion
2027-02
later than 18 of 67 live
Registered
178th of 189
by date

Among the 189 studies in Overweight with a site in Canada, this one is the 129th largest by planned enrollment of the 160 interventional ones that give a count, is one of 38 that started in 2026, is one of 79 with no phase, reaches primary completion later than 18 of the 67 other live ones, and was the 178th registered.

Overweight

3,613 studies on the registry are indexed under Overweight; 861 are open to participants now.

Browse Overweight studies →

Open to participants now

45 of the 189 studies in Overweight with a site in Canada are open now. Recruiting first, the newest first:

39 more — sign in →

All 45 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 534 Overweight studies recruiting now, 159 (30%) set no upper age limit and 347 (65%) stop at 75 or younger; 64 take children under 18; 205 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 189 studies in Overweight with a site in Canada, or all of them as a file.
02

Study summary

The goal of part 1 of this clinical trial is to investigate the tolerability of Lembas Edge in healthy adults. The objective of Part 2 of this study is to investigate the efficacy of Lembas Edge on postprandial glycemic control in prediabetic overweight and obese adults. The main questions it aims to answer are:

  • What is the tolerability of Lembas Edge?
  • What is the efficacy of Lembas Edge on postprandial glycemic control?

Researchers will compare Lembas Edge to placebo to see its effects. Participants will be asked to:

  • Provide blood samples.
  • Record their food and beverage intake in Part 2.
  • Complete a satiety questionnaire in Part 2.
  • Consume Lembas Edge or placebo as instructed.
03

Conditions studied

  • Postprandial Glycemic Control
  • Prediabetic Overweight and Obese Adults

Browse trials for

Keywords

  • prediabetic overweight and obese adults
  • postprandial glycemic control
  • Lembas
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria Part 1:

  1. Males \& females 18 years and older
  2. Females not of , defined as those who have undergone a sterilization procedure (e.g. hysterectomy, bilateral oophorectomy, bilateral tubal ligation, complete endometrial ablation) or have been for at least 1 year prior to screening Or, Individuals of child-bearing potential must have a negative baseline urine pregnancy test and agree to use a medically approved method of for the duration of the study. All hormonal birth control must have been in use for a minimum of three months. Acceptable methods of birth control include:

    • Hormonal contraceptives including oral contraceptives, hormone birth control patch (Ortho Evra), vaginal contraceptive ring (NuvaRing), injectable contraceptives (Depo-Provera, Lunelle), or hormone implant (Norplant System)
    • Double-barrier method
    • Intrauterine devices
    • Non-heterosexual lifestyle and agrees to use contraception if planning on changing to heterosexual partner(s)
    • Vasectomy of partner at least 6 months prior to screening
    • Abstinence and agrees to use contraception if planning on becoming sexually active during the study
  3. Agrees to maintain current lifestyle habits (diet, physical activity, medications, supplements, and sleep) as much as possible throughout the study
  4. Provided voluntary, written, to participate in the study
  5. Healthy as determined by medical history as assessed by the Qualified Investigator (QI)

Inclusion Criteria Part 2:

  1. Males \& females 18 years and older
  2. (BMI) between 25.0 and 34.9 kg/m2
  3. Females not of child-bearing potential, defined as those who have undergone a sterilization procedure (e.g. hysterectomy, bilateral oophorectomy, bilateral tubal ligation, complete endometrial ablation) or have been post-menopausal for at least 1 year prior to screening Or, Individuals of child-bearing potential must have a negative baseline urine pregnancy test and agree to use a medically approved method of birth control for the duration of the study. All hormonal birth control must have been in use for a minimum of three months. Acceptable methods of birth control include:

    • Hormonal contraceptives including oral contraceptives, hormone birth control patch (Ortho Evra), vaginal contraceptive ring (NuvaRing), injectable contraceptives (Depo-Provera, Lunelle), or hormone implant (Norplant System)
    • Double-barrier method
    • Intrauterine devices
    • Non-heterosexual lifestyle and agrees to use contraception if planning on changing to heterosexual partner(s)
    • Vasectomy of partner at least 6 months prior to screening
    • Abstinence and agrees to use contraception if planning on becoming sexually active during the study
  4. (HbA1c) of 5.7-6.4% at screening
  5. Willingness to complete questionnaires, records and diaries associated with the study and to complete clinic visits
  6. Agrees to maintain current lifestyle habits (diet, physical activity, medications, supplements, and sleep) as much as possible throughout the study
  7. Provided voluntary, written, informed consent to participate in the study
  8. Healthy as determined by medical history as assessed by the Qualified Investigator (QI)

Exclusion Criteria Part 1:

  1. Individuals who are pregnant, breast feeding, or planning to become pregnant during the study
  2. Allergy (including alpha-gal syndrome), sensitivity, intolerance, or dietary restriction preventing consumption of product
  3. Unstable metabolic disease or chronic diseases as assessed by the QI
  4. Current or history of any significant diseases of the gastrointestinal tract as assessed by the QI
  5. Unstable hypertension. Treatment on a stable dose of medication for at least 3 months will be considered by the QI (See Section 7.3)
  6. Type I or Type II diabetes
  7. Significant cardiovascular event in the past 6 months. Participants with no significant cardiovascular event on stable medication may be included after assessment by the QI on a case-by-case basis
  8. History of or current diagnosis with kidney and/or liver diseases as assessed by the QI on a case-by-case basis, with the exception of history of kidney stones in participants who are symptom free for 6 months
  9. Self-reported confirmation of current or pre-existing thyroid condition. Treatment on a stable dose of medication for at least 3 months will be considered by the QI
  10. Major surgery in the past 3 months or individuals who have planned surgery during the course of the study. Participants with minor surgery will be considered on a case-by-case basis by the QI
  11. Cancer, except skin basal cell carcinoma completely excised with no chemotherapy or radiation with a follow up that is negative. Volunteers with cancer in full remission for more than five years after diagnosis are acceptable
  12. Individuals with an disease or are immune compromised as assessed by the QI
  13. Self-reported confirmation of a (HIV)-, - and/or C-positive diagnosis as assessed by the QI
  14. Self-reported confirmation of blood/bleeding disorders as assessed by the QI
  15. Use of prescribed medical cannabinoid products
  16. Chronic use of cannabinoid products (>2 times/week). Occasional users will be required to washout and abstain for the duration of the study period
  17. Regular use of tobacco or nicotine products in the past six months, as assessed by the QI. Occasional users will be required to washout and abstain for the duration of the study period
  18. Alcohol intake average of >2 standard drinks per day as assessed by the QI
  19. Alcohol or drug abuse within the last 12 months
  20. Current use of prescribed and/or over-the-counter (OTC) medications, supplements, and/or consumption of food/drinks that may impact the safety of the investigational product (Sections 7.3.1 and 7.3.2)
  21. Blood donation 30 days prior to baseline, during the study, or a planned donation within 30 days of the last study visit
  22. Participation in other clinical research studies 30 days prior to baseline, as assessed by the QI
  23. Individuals who are unable to give informed consent
  24. Any other condition or lifestyle factor, that, in the opinion of the QI, may adversely affect the participant's ability to complete the study or its measures or pose significant risk to the participant

Exclusion Criteria Part 2:

  1. Individuals who are pregnant, breast feeding, or planning to become pregnant during the study
  2. Allergy (including alpha-gal syndrome), sensitivity, intolerance, or dietary restriction preventing consumption of investigational product or placebo ingredients or the standardized meal
  3. Poor venous access as assessed by the QI
  4. Change in body weight greater than 5 kg within 3 months prior to starting study
  5. Currently on or planning to initiate a body weight reduction diet during the study
  6. Self reported vigorous exercise >120 minutes/week
  7. Obesity induced by endocrinologic or genetic disorders or monogenetic or syndromic forms of obesity
  8. Family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN-2)
  9. Unstable metabolic disease or chronic diseases, including pancreatitis, as assessed by the QI
  10. Current diagnosis with gastroesophageal reflux disease (GERD) or hiatal hernia
  11. Current or history of any significant diseases of the gastrointestinal tract as assessed by the QI
  12. Unstable hypertension. Treatment on a stable dose of medication for at least 3 months will be considered by the QI (See Section 7.3)
  13. Type I or Type II diabetes
  14. Significant cardiovascular event in the past 6 months. Participants with no significant cardiovascular event on stable medication may be included after assessment by the QI on a case-by-case basis
  15. History of or current diagnosis with kidney and/or liver diseases as assessed by the QI on a case-by-case basis, with the exception of history of kidney stones in participants who are symptom free for 6 months
  16. Self-reported confirmation of current or pre-existing thyroid condition. Treatment on a stable dose of medication for at least 3 months will be considered by the QI
  17. Major surgery in the past 3 months or individuals who have planned surgery during the course of the study. Participants with minor surgery will be considered on a case-by-case basis by the QI
  18. Cancer, except skin basal cell carcinoma completely excised with no chemotherapy or radiation with a follow up that is negative. Volunteers with cancer in full remission for more than five years after diagnosis are acceptable
  19. Individuals with an autoimmune disease or are immune compromised as assessed by the QI
  20. Self-reported confirmation of a HIV-, Hepatitis B- and/or C-positive diagnosis as assessed by the QI
  21. Self-reported confirmation of blood/bleeding disorders as assessed by the QI
  22. Use of prescribed medical cannabinoid products
  23. Chronic use of cannabinoid products (>2 times/week). Occasional users will be required to washout and abstain for the duration of the study period
  24. Regular use of tobacco or nicotine products in the past six months, as assessed by the QI. Occasional users will be required to washout and abstain for the duration of the study period
  25. Alcohol intake average of >2 standard drinks per day as assessed by the QI
  26. Alcohol or drug abuse within the last 12 months
  27. Current use of prescribed and/or over-the-counter (OTC) medications, supplements, and/or consumption of food/drinks that may impact the glucose metabolism or efficacy of the investigational product (Sections 7.3.1 and 7.3.2)
  28. Blood donation 30 days prior to baseline, during the study, or a planned donation within 30 days of the last study visit
  29. Participation in other clinical research studies 30 days prior to baseline, as assessed by the QI
  30. Individuals who are unable to give informed consent
  31. Any other condition or lifestyle factor, that, in the opinion of the QI, may adversely affect the participant's ability to complete the study or its measures or pose significant risk to the participant
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
35 participants (estimated)

Study arms

  • Experimental
    Low Dose Lembas Edge

    Participants will be instructed to take 3 capsules of the study product in a fasted state 120 minutes before a standardized breakfast.

    Dietary Supplement: Low dose alpha-galactosidase-derived peptide

  • Experimental
    Medium Dose Lembas Edge

    Participants will be instructed to take 3 capsules of the study product in a fasted state 120 minutes before a standardized breakfast.

    Dietary Supplement: Medium dose alpha-galactosidase-derived peptide

  • Experimental
    High Dose Lembas Edge

    In part 1, participants will be instructed to take 3 capsules daily (as a single dose) in the morning until the day prior to their end of study visit (Day 13). In part 2, participants will be instructed to take 3 capsules of the study product in a fasted state 120 minutes before a standardized breakfast.

    Dietary Supplement: High dose alpha-galactosidase-derived peptide

  • Placebo comparator
    Placebo

    In part 1, participants will be instructed to take 3 capsules daily (as a single dose) in the morning until the day prior to their end of study visit (Day 13). In part 2, participants will be instructed to take 3 capsules of the study product in a fasted state 120 minutes before a standardized breakfast.

    Dietary Supplement: Placebo

Interventions

  • Dietary supplementLow dose alpha-galactosidase-derived peptide

    Participants will be instructed to take 3 capsules of the study product in a fasted state 120 minutes before a standardized breakfast.

  • Dietary supplementMedium dose alpha-galactosidase-derived peptide

    Participants will be instructed to take 3 capsules of the study product in a fasted state 120 minutes before a standardized breakfast.

  • Dietary supplementHigh dose alpha-galactosidase-derived peptide

    In part 1, participants will be instructed to take 3 capsules daily (as a single dose) in the morning until the day prior to their end of study visit (Day 13). In part 2, participants will be instructed to take 3 capsules of the study product in a fasted state 120 minutes before a standardized breakfast.

  • Dietary supplementPlacebo

    In part 1, participants will be instructed to take 3 capsules daily (as a single dose) in the morning until the day prior to their end of study visit (Day 13). In part 2, participants will be instructed to take 3 capsules of the study product in a fasted state 120 minutes before a standardized breakfast.

06

What researchers measure

Primary outcomes

  1. Incidence of post-emergent adverse events (AE)

    Part 1. Incidence of post-emergent adverse events (AE)

    Time frame: Day 0 to 14

  2. Clinically relevant changes in blood pressure after supplementation

    Part 1. Clinically relevant changes in blood pressure (mmHg) after supplementation

    Time frame: Day 0 to 14

  3. Clinically relevant changes in heart rate after supplementation

    Part 1. Clinically relevant changes in heart rate (beats per minute) after supplementation

    Time frame: Day 0 to 14

  4. Clinically relevant changes in aspartate aminotransferase

    Part 1. Clinically relevant changes in aspartate aminotransferase (U/L) after supplementation.

    Time frame: Day 0 to 14

  5. Clinically relevant changes in alanine aminotransferase

    Part 1. Clinically relevant changes in alanine aminotransferase (U/L) after supplementation.

    Time frame: Day 0 to 14

  6. Clinically relevant changes in alkaline phosphatase

    Part 1. Clinically relevant changes in alkaline phosphatase (U/L) after supplementation.

    Time frame: Day 0 to 14

  7. Clinically relevant changes in total bilirubin

    Part 1. Clinically relevant changes in total bilirubin (micromole/litre) after supplementation.

    Time frame: Day 0 to 14

  8. Clinically relevant changes in creatinine

    Part 1. Clinically relevant changes in creatinine (micromole/litre) after supplementation.

    Time frame: Day 0 to 14

  9. Clinically relevant changes in sodium

    Part 1. Clinically relevant changes in sodium (mmol/L) after supplementation.

    Time frame: Day 0 to 14

  10. Clinically relevant changes in potassium

    Part 1. Clinically relevant changes in potassium (mmol/L) after supplementation.

    Time frame: Day 0 to 14

  11. Clinically relevant changes in chloride

    Part 1. Clinically relevant changes in chloride (mmol/L) after supplementation.

    Time frame: Day 0 to 14

  12. Clinically relevant changes in estimated glomerular filtration rate

    Part 1. Clinically relevant changes in estimated glomerular filltration rate (mL/min/1.73 m\^2) after supplementation.

    Time frame: Day 0 to 14

  13. Clinically relevant changes in glucose

    Part 1. Clinically relevant changes in glucose (mmol/L) after supplementation.

    Time frame: Day 0 to 14

  14. Clinically relevant changes in red blood cell count

    Part 1. Clinically relevant changes in red blood cell count (x 10\^12/L) after supplementation

    Time frame: Day 0 to 14

  15. Clinically relevant changes in white blood cell count

    Part 1. Clinically relevant changes in white blood cell count (x 10\^9/L) after supplementation

    Time frame: Day 0 to 14

  16. Clinically relevant changes in platelet count

    Part 1. Clinically relevant changes in platelet count (x 10\^9/L) after supplementation

    Time frame: Day 0 to 14

  17. Clinically relevant changes in hemoglobin

    Part 1. Clinically relevant changes in hemoglobin (g/L) after supplementation

    Time frame: Day 0 to 14

  18. Clinically relevant changes in hematocrit

    Part 1. Clinically relevant changes in hematocrit (L/L) after supplementation

    Time frame: Day 0 to 14

  19. Clinically relevant changes in red blood cell indices (MCV - Mean Corpuscular Volume)

    Part 1. Clinically relevant changes in MCV (fL) after supplementation

    Time frame: Day 0 to 14

  20. Clinically relevant changes in red blood cell indices (MCH - Mean Corpuscular Hemoglobin)

    Part 1. Clinically relevant changes in MCH (pg) after supplementation

    Time frame: Day 0 to 14

  21. Clinically relevant changes in red blood cell indices (MCHC - Mean Corpuscular Hemoglobin Concentration)

    Part 1. Clinically relevant changes in MCHC (g/L) after supplementation

    Time frame: Day 0 to 14

  22. Clinically relevant changes in RDW - Red Cell Distribution Width

    Part 1. Clinically relevant changes in RDW (%) after supplementation

    Time frame: Day 0 to 14

  23. Clinically relevant changes in red blood cell indices (MPV - Mean Platelet Volume)

    Part 1. Clinically relevant changes in MPV (fL) after supplementation

    Time frame: Day 0 to 14

  24. The difference in postprandial glucose between Lembas Edge and placebo

    Part 2. The difference in postprandial glucose, as assessed by incremental area under the curve (iAUC) (0-120 min), between Lembas Edge (high dose, medium dose, low dose) and placebo.

    Time frame: Visit 2 (day 1) to Visit 5 (day 22)

  25. The height of the postprandial glucose peak and nadir post meal between Lembas Edge and placebo

    Part 2. The height of the postprandial glucose peak and nadir post meal between Lembas Edge (high dose, medium dose, low dose) and placebo.

    Time frame: Visit 2 (day 1) to Visit 5 (day 22)

Secondary outcomes

  1. The difference in postprandial glucose iAUC (0-240 min) between Lembas Edge and placebo

    Part 2. The difference in postprandial glucose, as assessed by iAUC (0-240 min), between Lembas Edge (high dose, medium dose, low dose) and placebo

    Time frame: Visit 2 (day 1) to Visit 5 (day 22)

  2. The difference in postprandial insulin between Lembas Edge and placebo

    Part 2. The difference in postprandial insulin, as assessed by iAUC (0-120 min) and iAUC (0-240 min), between Lembas Edge (high dose, medium dose, low dose) and placebo

    Time frame: Visit 2 (day 1) to Visit 5 (day 22)

  3. The difference in self-reported satiety scores between Lembas Edge and placebo

    Part 2. The difference in self-reported satiety scores, as assessed by iAUC (0-240 min), between Lembas Edge (high dose, medium dose, low dose) and placebo

    Time frame: Visit 2 (day 1) to Visit 5 (day 22)

  4. The difference in total calories consumed from the standardized meal between Lembas Edge an placebo

    Part 2. The difference in total calories consumed from the standardized meal provided on an ad libitum basis at time = 240 minutes between Lembas Edge (high dose, medium dose, low dose) and placebo

    Time frame: Visit 2 (day 1) to Visit 5 (day 22), time = 240 minutes

Other outcomes

  1. Change in fasting glucose from baseline to day 14 after supplementation

    Part 1. The change in fasting glucose from baseline to day 14 after supplementation

    Time frame: Day 0 to 14

  2. Change in fasting insulin from baseline to day 14 after supplementation

    Part 1. The change in fasting insulin from baseline to day 14 after supplementation

    Time frame: Day 0 to 14

  3. Change in fasting HOMA-IR from baseline to day 14 after supplementation

    Part 1. The change in Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) from baseline to day 14 after supplementation

    Time frame: Day 0 to 14

  4. Part 2. Incidence of post-emergent adverse events (AE)

    Part 2. Incidence of post-emergent adverse events (AE)

    Time frame: Visit 1 (day -45 to -1) to visit 5 (day 22)

  5. The difference in postprandial peptide YY (PYY) between Lembas Edge and placebo

    Part 2. The difference in postprandial PYY, as assessed by iAUC (0-240 min), between Lembas Edge (high dose, medium dose, low dose) and placebo

    Time frame: Day 1 to 22

  6. The difference in postprandial GIP (Glucose-Dependent Insulinotropic Polypeptide) between Lembas Edge and placebo

    Part 2. The difference in postprandial GIP, as assessed by iAUC (0-240 min), between Lembas Edge (high dose, medium dose, low dose) and placebo

    Time frame: Day 1 to 22

  7. The difference in postprandial Glucagon-Like Peptide-1 (GLP-1) between Lembas Edge and placebo

    Part 2. The difference in postprandial GLP-1, as assessed by iAUC (0-240 min), between Lembas Edge (high dose, medium dose, low dose) and placebo

    Time frame: Day 1 to 22

07

Study locations

1 of 1 sites recruiting
08

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2026 (actual). Primary completion is estimated for Feb 2027, 4 months after the start.

Of 112 industry-sponsored interventional studies with no phase under Overweight, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 25. This study's planned 4 months is below that.

Counting every sponsor, half of 1,420 studies reached it within 17 months; a quarter within 8 and three quarters within 38.

Start moved once since we started tracking on Sep 25, 2026: Sep 2026 → Oct 2026, on Sep 25, 2026.

Primary completion moved once since we started tracking on Sep 25, 2026: Jan 2027 → Feb 2027, on Nov 12, 2026.

Completion moved once since we started tracking on Sep 25, 2026: Jan 2027 → Feb 2027, on Nov 12, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 14, 2026
First posted
Jul 17, 2026
StartActual
Oct 21, 2026was Sep 2026
Primary completionEst.
Feb 2027was Jan 2027
CompletionEst.
Feb 2027was Jan 2027
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 12, 2026
Sites
KGK Science Inc. is now Recruiting
Nov 12, 2026
Start date
Sep 2026→Oct 2026
Sep 25, 2026
Primary completion
Jan 2027→Feb 2027
Nov 12, 2026
Study completion
Jan 2027→Feb 2027
Nov 12, 2026
Secondary outcomes
1 added
What changed in the outcomes
  • AddedThe difference in total calories consumed from the standardized meal between Lembas Edge an placeboTime frame: Visit 2 (day 1) to Visit 5 (day 22), time = 240 minutes
Sep 25, 2026
Contact
Study contact changed: e•••@kgkscience.com · •••4551→p•••@kgkscience.com · •••9374. See the current contact
Nov 12, 2026
Show all 2 updates
  1. Nov 12, 2026
    Not yet recruiting→Recruiting
    KGK Science Inc. is now Recruiting
    Primary completion Jan 2027→Feb 2027
    Study completion Jan 2027→Feb 2027
    Contact Study contact changed: e•••@kgkscience.com · •••4551→p•••@kgkscience.com · •••9374. See the current contact
    + 1 other change: verification date
  2. Sep 25, 2026
    Start date Sep 2026→Oct 2026
    Secondary outcomes 1 added
    What changed in the outcomes
    • AddedThe difference in total calories consumed from the standardized meal between Lembas Edge an placeboTime frame: Visit 2 (day 1) to Visit 5 (day 22), time = 240 minutes
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07711288
Lead sponsor
Lembas
Collaborators
KGK Science Inc.
Responsible party
Sponsor
First posted
Jul 17, 2026
Start date
Oct 21, 2026
Primary completion
Feb 2027 (estimated)
Completion
Feb 2027 (estimated)
Last update
Nov 12, 2026

Study contacts

Nisrine Zakaria, PhD
Contact
participate@kgkscience.com
519-438-9374 ext. x240

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion